CARLSBAD, Calif.--(BUSINESS WIRE)--Life Technologies Corporation (NASDAQ: LIFE), a provider of innovative life science solutions, announced it will use human embryonic stem cells to develop new models of Lou Gehrig’s Disease and other neurodegenerative diseases with a grant it received this week from the California Institute for Regenerative Medicine (CIRM), a state agency tasked with providing funding for stem cell research at California universities, private companies and research institutions.
